EUVIMEDEUVIMED entdecken
Vergleichsstudie

Comparison of Nanoliposomal Irinotecan Plus Fluorouracil/Leucovorin and S‐1, Irinotecan, and Oxaliplatin as Second‐Line Chemotherapy After Gemcitabine Plus Nab‐Paclitaxel for Unresectable Pancreatic Cancer

Masahiro Itonaga, Reiko Ashida, Takashi Tamura iD, Yasunobu Yamashita iD, Yuki Kawaji, Takahiro Shishimoto, Hiromu Morishita, Keisuke Hanada, Fumiyoshi Kojima, Masayuki Kitano iD

Journal of Hepato-Biliary-Pancreatic Sciences · 2026

DOI: 10.1002/jhbp.70122 ↗

Kurz gefasst

Vergleichsstudie in der Zeitschrift Journal of Hepato-Biliary-Pancreatic Sciences, 2026. Verfasst von Masahiro Itonaga und 9 weiteren Autor:innen. Beteiligte Einrichtung: Second Department of Internal Medicine, Wakayama Medical University, Wakayama, Japan. Hauptthemen laut MEDLINE: Pancreatic Neoplasms, Antineoplastic Combined Chemotherapy Protocols. Die Arbeit nennt 30 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Objectives

The optimal second‐line chemotherapy after gemcitabine plus nab‐paclitaxel (GnP) for unresectable pancreatic cancer (PC) remains unclear. This study compared the efficacy and safety of nanoliposomal irinotecan plus fluorouracil/leucovorin (NFF) and S‐1, irinotecan, and oxaliplatin (S‐IROX) after GnP failure.

Methods

This single‐center retrospective cohort study included patients with unresectable PC refractory to GnP who received NFF or S‐IROX between July 2020 and June 2024. Progression‐free survival (PFS), overall survival (OS), tumor response, and adverse events were evaluated. Prognostic factors were also assessed with subgroup analyses.

Results

Seventy‐nine patients were analyzed (NFF, n = 55; S‐IROX, n = 24). Median PFS was significantly longer with S‐IROX than with NFF (6.29 vs. 3.45 months; p = 0.048), and the overall response rate was higher (29% vs. 9%; p = 0.038). Median OS did not differ significantly (12.81 vs. 10.64 months; p = 0.170). The incidence of grade ≥ 3 adverse events was comparable. Multivariate analysis identified S‐IROX, modified Glasgow Prognostic Score (mGPS) 0, and CA19‐9 < 373 IU/L as independent predictors of longer PFS, while mGPS 0 and CA19‐9 < 373 IU/L were associated with longer OS. Subgroup analyses showed favorable outcomes with S‐IROX in locally advanced disease.

Conclusions

S‐IROX may be an effective and safe second‐line option after GnP, particularly for locally advanced PC.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Pancreatic NeoplasmsAntineoplastic Combined Chemotherapy ProtocolsHumansIrinotecanRetrospective StudiesPaclitaxelAlbuminsLeucovorinFluorouracilTegafurOxonic AcidDeoxycytidineDrug CombinationsOxaliplatinFemaleMaleGemcitabineAgedMiddle AgedLiposomes

Stichwörter der Autor:innen

S‐IROXgemcitabine plus nab‐paclitaxel failurenanoliposomal irinotecanpancreatic cancersecond‐line chemotherapy

Substanzen

IrinotecanPaclitaxelAlbuminsLeucovorinFluorouracilTegafurOxonic AcidDeoxycytidineDrug CombinationsOxaliplatin

Autor:innen und Institutionen

  • Second Department of Internal Medicine, Wakayama Medical University, Wakayama, Japan.
  • Clinical Study Support Center, Wakayama Medical University, Wakayama, Japan.
  • Department of Human Pathology, Wakayama Medical University, Wakayama, Japan.

ORCID-Profile: Takashi Tamura, Yasunobu Yamashita, Masayuki Kitano

Zitieren

APA

Itonaga, M., Ashida, R., Tamura, T., Yamashita, Y., Kawaji, Y., Shishimoto, T., Morishita, H., Hanada, K., Kojima, F., & Kitano, M. (2026). Comparison of Nanoliposomal Irinotecan Plus Fluorouracil/Leucovorin and S‐1, Irinotecan, and Oxaliplatin as Second‐Line Chemotherapy After Gemcitabine Plus Nab‐Paclitaxel for Unresectable Pancreatic Cancer. Journal of Hepato-Biliary-Pancreatic Sciences. https://doi.org/10.1002/jhbp.70122

Vancouver

Itonaga M, Ashida R, Tamura T, Yamashita Y, Kawaji Y, Shishimoto T, et al. Comparison of Nanoliposomal Irinotecan Plus Fluorouracil/Leucovorin and S‐1, Irinotecan, and Oxaliplatin as Second‐Line Chemotherapy After Gemcitabine Plus Nab‐Paclitaxel for Unresectable Pancreatic Cancer. Journal of Hepato-Biliary-Pancreatic Sciences. 2026. doi:10.1002/jhbp.70122

BibTeX
@article{Itonaga2026,
  author = {Itonaga, Masahiro and Ashida, Reiko and Tamura, Takashi and Yamashita, Yasunobu and Kawaji, Yuki and Shishimoto, Takahiro and Morishita, Hiromu and Hanada, Keisuke and Kojima, Fumiyoshi and Kitano, Masayuki},
  title = {Comparison of Nanoliposomal Irinotecan Plus Fluorouracil/Leucovorin and S‐1, Irinotecan, and Oxaliplatin as Second‐Line Chemotherapy After Gemcitabine Plus Nab‐Paclitaxel for Unresectable Pancreatic Cancer},
  journal = {Journal of Hepato-Biliary-Pancreatic Sciences},
  year = {2026},
  doi = {10.1002/jhbp.70122}
}
Kostenlos starten →